A panel of external advisors from the U.S. Food and Drug Administration (FDA) voted overwhelmingly to support the emergency use of Pfizer Inc.’s coronavirus vaccine, paving the way for the agency to authorize injection into a nation that has lost more than 285,000 lives by COVID-19.
The committee voted 17-4 to see that the known benefits of the vaccine, developed by Pfizer with Germany’s BioNTech, outweighed the risks in adults 16 years of age or older after receiving the injection. A panel member abstained.
